NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage
biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on
myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on
Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain. These
presentations will be made by the Company’s collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic.
Abstract Details:
Poster Presentation:
Date: May 4th through May 6th
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients
Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial
Oral Presentation:
Date: Saturday May 6th
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter: Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC
Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS)
Additional details and content from these presentations will be available on the Company’s website on the day of the
presentations.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small
molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead
candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways.
Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against
specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova
has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with
Onconova’s lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit
http://www.onconova.com.
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics Lisa.Sher@mbsvalue.com / (212) 750-5800
